Levetiracetam (Epilepsy)

Gestational diabetes

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12502
R47875		 Mari (Levetiracetam), 2022 Gestational diabetes throughout pregnancy retrospective cohort exposed to other treatment, sick Adjustment: No 0.19 [0.01;5.20] C 0/17   1/11 1 17
ref
S8083
R24694		 Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.68 [0.01;39.07] C
excluded (control group) 		0/10   0/7 0 10
ref
S8081
R24674		 Aydin (Levetiracetam) (Controls unexposed, sick), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 0.72 [0.03;19.34] C 0/10   1/22 1 10
ref
Total 2 studies 0.37 [0.04;3.82] 2 27
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mari (Levetiracetam), 2022Mari, 2022 1 0.19[0.01; 5.20]11750%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: unclear Aydin (Levetiracetam) (Controls unexposed, sick), 2020Aydin, 2020 2 0.72[0.03; 19.34]11050%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.37[0.04; 3.82]2270.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.37[0.04; 3.82]2270%NAMari (Levetiracetam), 2022 Aydin (Levetiracetam) (Controls unexposed, sick), 2020 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.72[0.03; 19.34]110 -NAAydin (Levetiracetam) (Controls unexposed, sick), 2020 1 exposed to other treatment, sickexposed to other treatment, sick 0.19[0.01; 5.20]117 -NAMari (Levetiracetam), 2022 1 Tags Adjustment   - No  - No 0.37[0.04; 3.82]2270%NAMari (Levetiracetam), 2022 Aydin (Levetiracetam) (Controls unexposed, sick), 2020 2 All studiesAll studies 0.37[0.04; 3.82]2270%NAMari (Levetiracetam), 2022 Aydin (Levetiracetam) (Controls unexposed, sick), 2020 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8083

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.72[0.03; 19.34]110 -NAAydin (Levetiracetam) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.32[0.02; 4.11]1270%NAMari (Levetiracetam), 2022 Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 20.510.01.0